AVANOS MEDICAL (AVNS) Competitors $10.74 -0.05 (-0.46%) Closing price 08/13/2025 03:59 PM EasternExtended Trading$10.74 +0.00 (+0.05%) As of 08/13/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVNS vs. EYE, LMAT, CNMD, LQDA, ENOV, AORT, CDRE, NVCR, SSII, and ESTAShould you be buying AVANOS MEDICAL stock or one of its competitors? The main competitors of AVANOS MEDICAL include National Vision (EYE), LeMaitre Vascular (LMAT), CONMED (CNMD), Liquidia Technologies (LQDA), Enovis (ENOV), Artivion (AORT), Cadre (CDRE), NovoCure (NVCR), SS Innovations International (SSII), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry. AVANOS MEDICAL vs. Its Competitors National Vision LeMaitre Vascular CONMED Liquidia Technologies Enovis Artivion Cadre NovoCure SS Innovations International Establishment Labs National Vision (NASDAQ:EYE) and AVANOS MEDICAL (NYSE:AVNS) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations. Is EYE or AVNS more profitable? National Vision has a net margin of -0.75% compared to AVANOS MEDICAL's net margin of -66.89%. AVANOS MEDICAL's return on equity of 6.16% beat National Vision's return on equity.Company Net Margins Return on Equity Return on Assets National Vision-0.75% 3.56% 1.49% AVANOS MEDICAL -66.89%6.16%4.57% Do insiders and institutionals have more ownership in EYE or AVNS? 95.2% of AVANOS MEDICAL shares are held by institutional investors. 2.7% of National Vision shares are held by insiders. Comparatively, 2.6% of AVANOS MEDICAL shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate EYE or AVNS? National Vision currently has a consensus price target of $24.73, suggesting a potential upside of 6.49%. Given National Vision's stronger consensus rating and higher probable upside, analysts plainly believe National Vision is more favorable than AVANOS MEDICAL.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score National Vision 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60AVANOS MEDICAL 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to EYE or AVNS? In the previous week, National Vision had 9 more articles in the media than AVANOS MEDICAL. MarketBeat recorded 12 mentions for National Vision and 3 mentions for AVANOS MEDICAL. National Vision's average media sentiment score of 1.01 beat AVANOS MEDICAL's score of -0.18 indicating that National Vision is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Vision 3 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AVANOS MEDICAL 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, EYE or AVNS? National Vision has higher revenue and earnings than AVANOS MEDICAL. National Vision is trading at a lower price-to-earnings ratio than AVANOS MEDICAL, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNational Vision$1.82B1.01-$28.50M-$0.18-129.00AVANOS MEDICAL$687.80M0.72-$392.10M-$10.07-1.07 Which has more risk & volatility, EYE or AVNS? National Vision has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, AVANOS MEDICAL has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. SummaryNational Vision beats AVANOS MEDICAL on 12 of the 16 factors compared between the two stocks. Get AVANOS MEDICAL News Delivered to You Automatically Sign up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVNS vs. The Competition Export to ExcelMetricAVANOS MEDICALMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$500.68M$6.97B$5.54B$20.85BDividend YieldN/A1.31%4.62%3.60%P/E Ratio-1.0725.2030.1328.50Price / Sales0.7268.92462.1681.45Price / Cash0.9121.6737.7523.46Price / Book0.645.698.495.45Net Income-$392.10M$176.29M$3.26B$994.60M7 Day Performance0.23%4.88%4.19%3.03%1 Month Performance-9.40%0.25%4.65%1.91%1 Year Performance-52.33%14.35%35.15%16.34% AVANOS MEDICAL Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVNSAVANOS MEDICAL1.6676 of 5 stars$10.74-0.5%N/A-52.4%$500.68M$687.80M-1.072,227High Trading VolumeEYENational Vision2.8221 of 5 stars$25.07+3.6%$24.18-3.5%+118.9%$1.91B$1.82B-75.9713,411Positive NewsLMATLeMaitre Vascular2.2164 of 5 stars$84.36+4.1%$97.83+16.0%+14.9%$1.83B$219.86M42.61490Insider TradeCNMDCONMED3.9773 of 5 stars$53.46+2.2%$59.80+11.9%-17.8%$1.62B$1.31B15.153,900News CoverageDividend AnnouncementLQDALiquidia Technologies3.0199 of 5 stars$19.48+10.2%$26.89+38.0%+89.6%$1.51B$14M-12.3350Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap UpENOVEnovis3.9157 of 5 stars$26.61+3.4%$55.60+109.0%-31.6%$1.47B$2.11B-1.917,367Earnings ReportAnalyst RevisionAORTArtivion3.1225 of 5 stars$32.06+3.7%$32.40+1.1%+74.5%$1.32B$388.54M-64.121,600Earnings ReportAnalyst DowngradeCDRECadre1.5201 of 5 stars$33.09+2.3%$37.50+13.3%-11.7%$1.31B$567.56M34.832,284Trending NewsAnalyst DowngradeAnalyst RevisionNVCRNovoCure4.4291 of 5 stars$11.76+3.9%$28.79+144.8%-36.1%$1.27B$605.22M-7.541,488SSIISS Innovations InternationalN/A$6.57+6.0%N/AN/A$1.20B$20.65M0.004Gap UpESTAEstablishment Labs2.1189 of 5 stars$42.72+3.3%$54.83+28.4%-9.6%$1.20B$166.02M-13.781,018Earnings Report Related Companies and Tools Related Companies National Vision Competitors LeMaitre Vascular Competitors CONMED Competitors Liquidia Technologies Competitors Enovis Competitors Artivion Competitors Cadre Competitors NovoCure Competitors SS Innovations International Competitors Establishment Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AVNS) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVANOS MEDICAL, INC. Please log in to your account or sign up in order to add this asset to your watchlist. Share AVANOS MEDICAL With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.